Drug Combination Extends Survival by More Than a Year in Metastatic Prostate Cancer
Dana-Farber Cancer InstituteMen with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group.